Ilya Rachman

Chief Executive Officer at IMMIX BIOPHARMA, INC.

Net worth: 10 M $ as of 2026-05-30

54 year

Consumer Services

Health Technology

Profile

Ilya Rachman is the founder of Immix Biopharma, Inc., founded in 2012, holding the title of Chairman & Chief Executive Officer.
The current job is Executive Chairman at Nexcella, Inc. Education history includes an MBA from the University of California, Los Angeles; graduate and doctorate degrees from the University of Illinois; and an undergraduate degree from the University of Iowa.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
IMMIX BIOPHARMA, INC. 2.1%	2026-05-21	1,141,683 ( 2.1% )	10 M $	2026-05-30

Ilya Rachman active positions

Companies	Position	Start
IMMIX BIOPHARMA, INC.	Chief Executive Officer	2011-12-31
Nexcella, Inc. Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases	Chairman	-

All active positions of Ilya Rachman

Training of Ilya Rachman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ilya Rachman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
University of California, Los Angeles University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Illinois University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Iowa University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Immix Biopharma, Inc. Immix Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cancer patients	Health Technology
Nexcella, Inc. Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases	Health Technology